Xanodyne Pharmaceuticals has emerged as the winning bidder for aaiPharma's pharmaceutical division. Xanodyne will pay $209 million and buy up to $30 million in services from aaiPharma. "We're extremely pleased that we've reached a favorable conclusion to the auction process," said aaiPharma's president and CEO Ludo Reynders. "This will significantly help the company in rebuilding its financial structure."
- read this press release for more